<p>Arista Wealth Management LLC 在第二季度获得了赛诺菲（NASDAQ:SNY - 免费报告）的新股份，根据其最近向 SEC 的披露。该基金购买了 7,890 股公司股票，价值约为 381,000 美元。</p>
<ul>
<li>分析师们对这些鲜为人知的生物制药股票情有独钟</li>
</ul>
<p>其他几家对冲基金和机构投资者最近也增加或减少了对该股票的持仓。Ameritas Advisory Services LLC 在第二季度获得了价值 28,000 美元的赛诺菲新股份。Accent Capital Management LLC 在第一季度获得了价值 29,000 美元的赛诺菲新股份。Eastern Bank 在第一季度将其赛诺菲持股增加了 121.0%。Eastern Bank 目前拥有 548 股公司股票，价值 30,000 美元，此前在上个季度又购买了 300 股。Banque Transatlantique SA 在第一季度获得了价值约 33,000 美元的赛诺菲新股份。最后，Golden State Wealth Management LLC 在第一季度将其赛诺菲持股增加了 619.3%。Golden State Wealth Management LLC 目前拥有 633 股公司股票，价值 35,000 美元，此前在上个季度又购买了 545 股。14.04% 的股票由机构投资者和对冲基金持有。</p>
<h2>华尔街分析师预测增长</h2>
<p>多家股票分析师对该公司发布了报告。德意志银行在 9 月 2 日的报告中将赛诺菲的评级从 “持有” 上调至 “买入”。Wall Street Zen 在 8 月 2 日的研究报告中将赛诺菲的评级从 “持有” 上调至 “买入”。摩根士丹利在 9 月 8 日的研究报告中将赛诺菲的评级从 “同等权重” 上调至 “增持”，并将其目标价格从 56.00 美元上调至 58.00 美元。摩根大通在 8 月 8 日的研究报告中将赛诺菲的评级从 “中性” 上调至 “增持”。最后，Weiss Ratings 在 10 月 8 日的研究报告中重申了对赛诺菲的 “持有（c）” 评级。两位投资分析师给予该股票 “强烈买入” 评级，六位给予 “买入” 评级，两位给予 “持有” 评级。根据 MarketBeat 的数据，赛诺菲目前的共识评级为 “买入”，平均目标价格为 62.67 美元。</p>
<ul>
<li>分析师认为这些股票的价值可能会翻倍</li>
</ul>
<p><strong>阅读我们关于 SNY 的最新报告</strong></p>
<h2>赛诺菲股票表现</h2>
<p>SNY 的股票在周五开盘价为 50.62 美元。该公司的流动比率为 1.27，速动比率为 0.94，债务股本比率为 0.19。该公司的市值为 1243 亿美元，市盈率为 12.17，PEG 比率为 1.22，贝塔值为 0.51。该股票的 50 日移动平均线为 48.49 美元，200 日移动平均线为 49.63 美元。赛诺菲的 12 个月低点为 44.62 美元，12 个月高点为 60.12 美元。</p>
<ul>
<li>Regeneron：它是价值与增长的完美生物科技股票吗？</li>
</ul>
<p>赛诺菲（NASDAQ:SNY - 获取免费报告）最后一次公布季度财报是在 7 月 31 日。该公司报告每股收益为 0.90 美元，低于共识预期的 0.96 美元（差 0.06 美元）。赛诺菲的净利润率为 21.47%，股本回报率为 16.86%。该公司在本季度的收入为 113.4 亿美元，而共识预期为 99.1 亿美元。去年同期，该公司每股收益为 1.73 美元。赛诺菲本季度的收入同比下降了 7.0%。作为一个整体，卖方分析师预测赛诺菲在当前年度的每股收益将达到 4.36 美元。</p>
<h2>赛诺菲公司简介</h2>
<p>（免费报告）</p>
<p>赛诺菲是一家医疗保健公司，专注于在美国、欧洲、加拿大及国际市场的治疗解决方案的研究、开发、生产和营销。它通过制药、疫苗和消费者医疗保健三个部门运营。该公司提供特种护理，如 DUPIXENT、神经学和免疫学、罕见疾病、肿瘤学和罕见血液疾病；糖尿病和心血管疾病的药物；以及已建立的处方产品。</p>
<h2>另见</h2>
<ul>
<li>五只我们更看好的股票，胜过赛诺菲</li>
<li>如何计算退休收入：MarketBeat 的计算器</li>
<li>这家 AI 芯片巨头可能是市场下一个大赢家</li>
<li>三只小盘股具有巨大的回报潜力</li>
<li>博通签署 OpenAI 协议：为什么这对 AVGO 股票是一个巨大的胜利</li>
<li>WallStreetBets 是什么，它们正在瞄准哪些股票？</li>
<li>机构正在推动 CrowdStrike 的下一轮上涨</li>
</ul>
<p><strong>想看看其他对冲基金持有的 SNY 吗？</strong> 访问 HoldingsChannel.com 以获取赛诺菲（NASDAQ:SNY - 免费报告）的最新 13F 文件和内部交易。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U05Z?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U05Z"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送电子邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在赛诺菲吗？</h2>
<p>在考虑赛诺菲之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而赛诺菲并不在名单上。</p>
<p>虽然赛诺菲目前在分析师中获得 “买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

赛诺菲

赛诺菲集团

<p>根据 SEC 的披露，Arista Wealth Management LLC 在第二季度收购了 7,890 股赛诺菲（NASDAQ:SNY），价值约为 381,000 美元。其他机构投资者也增加了对赛诺菲的持股。分析师们已将赛诺菲的评级上调，普遍评级为 “买入”，平均目标价为 62.67 美元。赛诺菲的股票开盘价为 50.62 美元，市值为 1243 亿美元。该公司报告上个季度每股收益为 0.90 美元，未达到预期，营收为 113.4 亿美元，同比下降 7%</p>

<p>Arista Wealth Management LLC acquired a new stake in Sanofi (NASDAQ:SNY - Free Report) in the 2nd quarter, according to its most recent disclosure with the SEC. The fund acquired 7,890 shares of the company's stock, valued at approximately $381,000.</p>
<div class="lb-trans"><p>Arista Wealth Management LLC 在第二季度获得了赛诺菲（NASDAQ:SNY - 免费报告）的新股份，根据其最近向 SEC 的披露。该基金购买了 7,890 股公司股票，价值约为 381,000 美元。</p>
</div><ul>
<li>Analysts Can't Get Enough of These Little-Known Biopharma Stocks</li>
</ul>
<div class="lb-trans"><ul>
<li>分析师们对这些鲜为人知的生物制药股票情有独钟</li>
</ul>
</div><p>Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Ameritas Advisory Services LLC acquired a new position in shares of Sanofi during the 2nd quarter worth $28,000. Accent Capital Management LLC acquired a new position in shares of Sanofi during the 1st quarter worth $29,000. Eastern Bank raised its holdings in shares of Sanofi by 121.0% during the 1st quarter. Eastern Bank now owns 548 shares of the company's stock worth $30,000 after buying an additional 300 shares in the last quarter. Banque Transatlantique SA acquired a new position in Sanofi in the 1st quarter worth about $33,000. Finally, Golden State Wealth Management LLC increased its holdings in Sanofi by 619.3% in the 1st quarter. Golden State Wealth Management LLC now owns 633 shares of the company's stock worth $35,000 after purchasing an additional 545 shares in the last quarter. 14.04% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>其他几家对冲基金和机构投资者最近也增加或减少了对该股票的持仓。Ameritas Advisory Services LLC 在第二季度获得了价值 28,000 美元的赛诺菲新股份。Accent Capital Management LLC 在第一季度获得了价值 29,000 美元的赛诺菲新股份。Eastern Bank 在第一季度将其赛诺菲持股增加了 121.0%。Eastern Bank 目前拥有 548 股公司股票，价值 30,000 美元，此前在上个季度又购买了 300 股。Banque Transatlantique SA 在第一季度获得了价值约 33,000 美元的赛诺菲新股份。最后，Golden State Wealth Management LLC 在第一季度将其赛诺菲持股增加了 619.3%。Golden State Wealth Management LLC 目前拥有 633 股公司股票，价值 35,000 美元，此前在上个季度又购买了 545 股。14.04% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>A number of equities analysts have issued reports on the company. Deutsche Bank Aktiengesellschaft raised Sanofi from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a report on Tuesday, September 2nd. Wall Street Zen upgraded Sanofi from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research report on Saturday, August 2nd. Morgan Stanley upgraded Sanofi from an &#34;equal weight&#34; rating to an &#34;overweight&#34; rating and upped their target price for the company from $56.00 to $58.00 in a research report on Monday, September 8th. JPMorgan Chase &amp; Co. upgraded Sanofi from a &#34;neutral&#34; rating to an &#34;overweight&#34; rating in a research report on Friday, August 8th. Finally, Weiss Ratings reaffirmed a &#34;hold (c)&#34; rating on shares of Sanofi in a research note on Wednesday, October 8th. Two investment analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat, Sanofi presently has a consensus rating of &#34;Buy&#34; and an average price target of $62.67.</p>
<div class="lb-trans"><p>多家股票分析师对该公司发布了报告。德意志银行在 9 月 2 日的报告中将赛诺菲的评级从 “持有” 上调至 “买入”。Wall Street Zen 在 8 月 2 日的研究报告中将赛诺菲的评级从 “持有” 上调至 “买入”。摩根士丹利在 9 月 8 日的研究报告中将赛诺菲的评级从 “同等权重” 上调至 “增持”，并将其目标价格从 56.00 美元上调至 58.00 美元。摩根大通在 8 月 8 日的研究报告中将赛诺菲的评级从 “中性” 上调至 “增持”。最后，Weiss Ratings 在 10 月 8 日的研究报告中重申了对赛诺菲的 “持有（c）” 评级。两位投资分析师给予该股票 “强烈买入” 评级，六位给予 “买入” 评级，两位给予 “持有” 评级。根据 MarketBeat 的数据，赛诺菲目前的共识评级为 “买入”，平均目标价格为 62.67 美元。</p>
</div><ul>
<li>Analysts Think These Stocks Could More Than Double in Value</li>
</ul>
<div class="lb-trans"><ul>
<li>分析师认为这些股票的价值可能会翻倍</li>
</ul>
</div><p><strong>Read Our Latest Report on SNY</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 SNY 的最新报告</strong></p>
</div><h2>Sanofi Stock Performance</h2>
<div class="lb-trans"><h2>赛诺菲股票表现</h2>
</div><p>Shares of SNY opened at $50.62 on Friday. The company has a current ratio of 1.27, a quick ratio of 0.94 and a debt-to-equity ratio of 0.19. The company has a market capitalization of $124.30 billion, a price-to-earnings ratio of 12.17, a PEG ratio of 1.22 and a beta of 0.51. The stock has a 50 day moving average of $48.49 and a 200 day moving average of $49.63. Sanofi has a 12 month low of $44.62 and a 12 month high of $60.12.</p>
<div class="lb-trans"><p>SNY 的股票在周五开盘价为 50.62 美元。该公司的流动比率为 1.27，速动比率为 0.94，债务股本比率为 0.19。该公司的市值为 1243 亿美元，市盈率为 12.17，PEG 比率为 1.22，贝塔值为 0.51。该股票的 50 日移动平均线为 48.49 美元，200 日移动平均线为 49.63 美元。赛诺菲的 12 个月低点为 44.62 美元，12 个月高点为 60.12 美元。</p>
</div><ul>
<li>Regeneron: Is It the Perfect Biotech Stock for Value and Growth?</li>
</ul>
<div class="lb-trans"><ul>
<li>Regeneron：它是价值与增长的完美生物科技股票吗？</li>
</ul>
</div><p>Sanofi (NASDAQ:SNY - Get Free Report) last announced its quarterly earnings data on Thursday, July 31st. The company reported $0.90 earnings per share for the quarter, missing the consensus estimate of $0.96 by ($0.06). Sanofi had a net margin of 21.47% and a return on equity of 16.86%. The firm had revenue of $11.34 billion for the quarter, compared to the consensus estimate of $9.91 billion. During the same period last year, the company posted $1.73 earnings per share. Sanofi's revenue for the quarter was down 7.0% on a year-over-year basis. As a group, sell-side analysts forecast that Sanofi will post 4.36 earnings per share for the current year.</p>
<div class="lb-trans"><p>赛诺菲（NASDAQ:SNY - 获取免费报告）最后一次公布季度财报是在 7 月 31 日。该公司报告每股收益为 0.90 美元，低于共识预期的 0.96 美元（差 0.06 美元）。赛诺菲的净利润率为 21.47%，股本回报率为 16.86%。该公司在本季度的收入为 113.4 亿美元，而共识预期为 99.1 亿美元。去年同期，该公司每股收益为 1.73 美元。赛诺菲本季度的收入同比下降了 7.0%。作为一个整体，卖方分析师预测赛诺菲在当前年度的每股收益将达到 4.36 美元。</p>
</div><h2>Sanofi Company Profile</h2>
<div class="lb-trans"><h2>赛诺菲公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.</p>
<div class="lb-trans"><p>赛诺菲是一家医疗保健公司，专注于在美国、欧洲、加拿大及国际市场的治疗解决方案的研究、开发、生产和营销。它通过制药、疫苗和消费者医疗保健三个部门运营。该公司提供特种护理，如 DUPIXENT、神经学和免疫学、罕见疾病、肿瘤学和罕见血液疾病；糖尿病和心血管疾病的药物；以及已建立的处方产品。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Sanofi</li>
<li>How to Calculate Retirement Income: MarketBeat’s Calculator</li>
<li>This AI Chip Giant Could Be the Market’s Next Big Winner</li>
<li>3 Small Caps With Big Return Potential</li>
<li>Broadcom Inks OpenAI Deal: Why It's A Huge Win for AVGO Stock</li>
<li>What Is WallStreetBets and What Stocks Are They Targeting?</li>
<li>Institutions Are Fueling CrowdStrike’s Next Leg Higher</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过赛诺菲</li>
<li>如何计算退休收入：MarketBeat 的计算器</li>
<li>这家 AI 芯片巨头可能是市场下一个大赢家</li>
<li>三只小盘股具有巨大的回报潜力</li>
<li>博通签署 OpenAI 协议：为什么这对 AVGO 股票是一个巨大的胜利</li>
<li>WallStreetBets 是什么，它们正在瞄准哪些股票？</li>
<li>机构正在推动 CrowdStrike 的下一轮上涨</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding SNY?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NASDAQ:SNY - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对冲基金持有的 SNY 吗？</strong> 访问 HoldingsChannel.com 以获取赛诺菲（NASDAQ:SNY - 免费报告）的最新 13F 文件和内部交易。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U05Z" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=SNY"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送电子邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Sanofi Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在赛诺菲吗？</h2>
</div><p>Before you consider Sanofi, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑赛诺菲之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sanofi wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而赛诺菲并不在名单上。</p>
</div><p>While Sanofi currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然赛诺菲目前在分析师中获得 “买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Arista Wealth Management LLC 收购了 7,890 股赛诺菲股票 $SNY